New CRISPR Therapy Shows Success in Reducing Cholesterol

Medical science is on the brink of a revolution in treating heart disease.

Traditionally, managing high cholesterol has required patients to take daily pills or receive regular injections for their entire lives.

However, new CRISPR-based therapies are shifting this paradigm toward a 'one-and-done' approach.

By using precise gene-editing technology, scientists can now 'switch off' specific genes in the liver that regulate lipid levels.

Recent trials for the therapy CTX310 have shown incredible promise.

A single infusion successfully reduced LDL cholesterol by over 50% in patients, with results lasting at least one year and no serious safety issues reported.

While other treatments, like those targeting the PCSK9 gene, have faced clinical hurdles, the field remains optimistic.

If future trials confirm these findings, we may see a future where cardiovascular risk is managed by a single, permanent genetic adjustment rather than a lifetime of medication.